BTIG on Opus Genetics (IRD): 'the path from here to BLA submission seems clear'

July 6, 2026 12:06 PM

BTIG analyst Thomas Shrader reiterated a Buy rating and $12.00 price target on Opus Genetics (NASDAQ: IRD).The analyst comments "Another ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found